In accordance with privacy legislation, Kedrion S.p.A., controller of the data collected through this website, hereby informs the user that this website does not use profiling cookies to send advertising messages in line with the preferences expressed when browsing the web. This website installs third party cookies. By continuing to browse, including by scrolling down and clicking on website elements, the user agrees to the company’s cookies policy.
For more information, also as regards the technical cookies used by the website and to object to the use of individual cookies, reference should be made to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
Key figures
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in over 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States, Hungary and Germany to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
PRESS RELEASES
Annual Results 2017
Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%
read moreKedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells
read more
KEDRION NOTES
For more information please contact: investor@kedrion.com
Where 